Search

Your search keyword '"Khoja, Leila"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Khoja, Leila" Remove constraint Author: "Khoja, Leila" Database Complementary Index Remove constraint Database: Complementary Index
23 results on '"Khoja, Leila"'

Search Results

1. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.

2. Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer.

3. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.

4. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.

7. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.

8. AR Signaling and the PI3K Pathway in Prostate Cancer.

9. Malignant bowel obstruction in advanced ovarian cancer.

10. Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).

11. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.

12. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.

13. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.

14. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

15. Pembrolizumab.

16. Dabrafenib in the treatment of metastatic or unresectable melanoma.

17. Circulating biomarkers in hepatocellular carcinoma.

20. Method validation of circulating tumour cell enumeration at low cell counts.

21. Increased treatment-related toxicity subsequent to an anti-PD-1 agent.

22. Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases.

Catalog

Books, media, physical & digital resources